KR100376305B1 - Healthy food composition for protecting hepatic - Google Patents
Healthy food composition for protecting hepatic Download PDFInfo
- Publication number
- KR100376305B1 KR100376305B1 KR10-2000-0045720A KR20000045720A KR100376305B1 KR 100376305 B1 KR100376305 B1 KR 100376305B1 KR 20000045720 A KR20000045720 A KR 20000045720A KR 100376305 B1 KR100376305 B1 KR 100376305B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- liver
- food composition
- health food
- hepatic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000002440 hepatic effect Effects 0.000 title description 5
- 235000001497 healthy food Nutrition 0.000 title 1
- 210000004185 liver Anatomy 0.000 claims abstract description 32
- 235000013402 health food Nutrition 0.000 claims abstract description 31
- 241001116389 Aloe Species 0.000 claims abstract description 10
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 10
- 241000209020 Cornus Species 0.000 claims abstract description 10
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 10
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 10
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 9
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 9
- 239000010865 sewage Substances 0.000 claims abstract description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 8
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 8
- 235000012907 honey Nutrition 0.000 claims abstract description 7
- 239000000052 vinegar Substances 0.000 claims abstract description 6
- 235000021419 vinegar Nutrition 0.000 claims abstract description 6
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 241000282374 Puma concolor Species 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 6
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 3
- 239000011574 phosphorus Substances 0.000 abstract description 3
- 241001356458 Gonorynchus greyi Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 244000061458 Solanum melongena Species 0.000 abstract 1
- 235000002597 Solanum melongena Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 28
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000002443 hepatoprotective effect Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 235000013399 edible fruits Nutrition 0.000 description 12
- 230000033001 locomotion Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 208000019423 liver disease Diseases 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 241000245665 Taraxacum Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 208000006454 hepatitis Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000001256 tonic effect Effects 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 244000241872 Lycium chinense Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 4
- 235000009685 Crataegus X maligna Nutrition 0.000 description 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 4
- 235000009486 Crataegus bullatus Nutrition 0.000 description 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 4
- 235000009682 Crataegus limnophila Nutrition 0.000 description 4
- 240000000171 Crataegus monogyna Species 0.000 description 4
- 235000004423 Crataegus monogyna Nutrition 0.000 description 4
- 235000002313 Crataegus paludosa Nutrition 0.000 description 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 201000006549 dyspepsia Diseases 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- 240000003173 Drymaria cordata Species 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000005473 carotenes Nutrition 0.000 description 3
- 150000001746 carotenes Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- -1 quince Chemical compound 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000239223 Arachnida Species 0.000 description 2
- 241000258957 Asteroidea Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 235000002787 Coriandrum sativum Nutrition 0.000 description 2
- 244000018436 Coriandrum sativum Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000019229 Spleen disease Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 244000131415 Zanthoxylum piperitum Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000027140 splenic disease Diseases 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- LFJQCDVYDGGFCH-SNVBAGLBSA-N (-)-β-phellandrene Chemical compound CC(C)[C@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-SNVBAGLBSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- MIJYXULNPSFWEK-LGSDIRQTSA-N (4as,6as,6br,10r,12ar)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C[C@@H](O)C(C)(C)C2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)CC5C4=CCC3[C@]21C MIJYXULNPSFWEK-LGSDIRQTSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FMIMFCRXYXVFTA-UHFFFAOYSA-N 3-Oxo-12-oleanen-28-oic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C FMIMFCRXYXVFTA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000010686 Agastache rugosa Nutrition 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 1
- 241000217377 Amblema plicata Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000584261 Artemisia messerschmidtiana Species 0.000 description 1
- 235000012313 Artemisia messerschmidtiana Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 1
- 241000132011 Atractylodes lancea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000123392 Hymenochaetaceae Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- 241000244359 Ligusticum jeholense Species 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- YPIQVCUJEKAZCP-UHFFFAOYSA-N Malotilate Chemical compound CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 YPIQVCUJEKAZCP-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000609829 Rubus sachalinensis Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000691199 Taraxacum platycarpum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 241000287436 Turdus merula Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NLZCOTZRUWYPTP-UHFFFAOYSA-N acacetin-7-O-beta-D-galactoside Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(CO)O1 NLZCOTZRUWYPTP-UHFFFAOYSA-N 0.000 description 1
- 229930192007 acanthoside Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- LFJQCDVYDGGFCH-UHFFFAOYSA-N beta-phellandrene Natural products CC(C)C1CCC(=C)C=C1 LFJQCDVYDGGFCH-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 125000000396 limonene group Chemical group 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000005817 liver abnormality Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229950000470 malotilate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MXEMKMNFLXVQBW-UHFFFAOYSA-N oleanoic acid Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MXEMKMNFLXVQBW-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- GWOKWCRSUJQOMD-UHFFFAOYSA-N tilianin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC=C2OC1C(O)C(O)C(O)C(CO)O1 GWOKWCRSUJQOMD-UHFFFAOYSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011579 vitamin B4 Substances 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 간장보호용 건강식품 조성물에 관한 것으로, 인진쑥 8 중량%, 상황 6 중량%, 영지 6 중량%, 산사자 4 중량%, 호사자 4 중량%, 달개비 4 중량%, 알로에 4 중량%, 복분자 4 중량%, 천궁 4 중량%, 계피 4 중량%, 구기자 4 중량%, 백출 4 중량%, 산수유 4 중량%, 곽향 4 중량%, 매실 4 중량%, 오갈피 4 중량%, 덩굴초 4 중량%, 백봉령 4 중량%, 하수오 4 중량%, 어성초 4 중량%, 민들레 4 중량%, 꿀 8%로 구성되어 간장보호에 뛰어난 효과가 있다.The present invention relates to a health food composition for liver protection, 8% by weight of phosphorus mugwort, 6% by weight of eggplant, 6% by weight of ganoderma lucidum, 4% by weight of lioness, 4% by weight of dead sandfish, 4% by weight of dalgi, 4% by weight of aloe, Bokbunja 4 Weight%, Cheongung 4%, Cinnamon 4%, Wolfberry 4%, Baekchul 4%, Cornus 4%, Wagyu 4%, Plum 4%, Ogalpi 4%, Vinegar 4%, Baekbongryeong It is composed of 4% by weight, 4% by weight of sewage, 4% by weight of effervescent vinegar, 4% by weight of dandelion, and 8% of honey.
Description
본 발명은 간장보호용 건강식품 조성물에 관한 것이다. 더욱 상세하게는, 인진쑥, 상황, 영지, 산사자, 호사자(원지), 달개비, 알로에, 복분자, 천궁, 계피, 구기자, 백출, 산수유, 곽향, 매실, 오갈피, 덩굴초, 백봉령, 하수오, 어성초, 민들레를 혼합하여 제조함으로써 기호성이 우수하고 간장보호에 효과가 있는 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition for liver protection. More specifically, Injin mugwort, situation, manor, mountain lion, lioness (origin), coriander, aloe, bokbunja, celestial, cinnamon, gojija, baekryu, cornus, gugyang, plum, ogalpi, vines, baekbongryeong, seoho, eoseongcho, It relates to a health food composition that is excellent in palatability by producing a mixture of dandelion and effective in protecting the liver.
음식의 대사에 있어 간장(liver)은 신체 장기에서 가장 중요한 기관의 하나이다. 간장은 체중의 2.5∼3%를 차지하며 신체에 있는 선기관 중에서 가장 크다. 성인의 간장의 무게는 약 1∼1.5 ㎏ 정도이다. 위치는 횡격막 아래 우측 상복부에 있으며, 낫 모양의 인대에 의해 좌우엽으로 나눠져 있다.The liver is one of the most important organs of the body in food metabolism. Soy makes up 2.5 to 3% of the body weight and is the largest organ in the body. The liver weight of adults is about 1 to 1.5 kg. It is located in the right upper abdomen below the diaphragm and is divided into left and right lobes by a sickle-shaped ligament.
생체에 있어서 간장은 주로 이하에 열거하는 3가지 기능을 갖는다. 즉 우선 제 1기능으로서, 간장은 소화선으로서 활동하고, 1일에 500∼1000cc의 담즙을 분비하여 소장에서의 지방의 소화 및 흡수를 돕는다. 또한, 제 2기능으로서, 간장은 각종 영양소의 체내에 있어서 화학적 변화, 저장 및 이용, 즉 중간 대사에 관여한다. 또한, 제 3기능으로서, 간장은 해독 작용을 행하고, 체외에서의 유해물질, 예를 들면 독물 및 체내에 만들어진 유독 물질에 산화, 환원, 응집 등의 해독처리를 가하거나 또는 이를 담즙에 섞어서 폐기하거나, 신장으로 보내서 뇨중에 배설한다.In living organisms, the liver mainly has three functions listed below. That is, as a first function, the liver acts as a digestive gland and secretes 500-1000 cc of bile per day to help digest and absorb fat in the small intestine. In addition, as a second function, the liver is involved in chemical alteration, storage and utilization, that is, intermediate metabolism in the body of various nutrients. In addition, as a third function, the liver has a detoxification effect, and detoxification treatment such as oxidation, reduction, agglomeration, etc. is applied to harmful substances in the body, for example, poisons and toxic substances made in the body, or mixed with bile for disposal. Send it to the kidneys to excrete it in urine.
간장의 혈류 중 약 80%는 장에서 흡수된 영양소를 간장에 운반하는 문맥(門脈)이며, 나머지 20%는 간장에 산소와 영양소를 운반하는 간장동맥이다. 따라서 간경변증에서 간장의 혈액 순환이 저해되면 문맥압의 항진으로 식도, 위, 장, 비장 등에 울혈이 생기고 여러 가지 증상이 나타난다. 간장은 문맥을 통해 운반되는 영양소의 분해·합성·저장 외에 담즙의 분비, 유독 물질의 해독과 배설 등 중요한 기능을 하며 신체내에서는 중간 대사의 중심적 역할을 이행하고 있다.About 80% of the liver's blood flow is the portal to the nutrients absorbed by the intestine, and the remaining 20% is the hepatic artery that carries oxygen and nutrients to the liver. Therefore, in liver cirrhosis, when blood circulation of the liver is inhibited, hypertension of the portal vein causes congestion of the esophagus, stomach, intestine, spleen, and various symptoms. The liver plays important roles such as bile secretion, detoxification and excretion of toxic substances in addition to the decomposition, synthesis and storage of nutrients carried through the portal.
간장기능에는 큰 대상 작용이 있고(간장의 4/5를 잘라도 생명의 위험은 없다) 재생 능력도 강하다. 간장의 혈류는 항상 일정하지는 않으며 어느 정도의 예비력을 가지고 있고 혈액의 저장 혹은 혈액량의 조절에 큰 역할을 한다. 문맥에서 간장으로 운반되는 영양소는 궁극적으로 간세포내에서 분해되어 에너지 급원이 되거나 재합성되어 간장에 저장되며 혹은 혈중에 방출된다.Hepatic function has a large target action (cutting 4/5 of the liver, there is no risk of life) and strong regeneration. Hepatic blood flow is not always constant and has some reserve and plays a large role in the storage of blood or the regulation of blood volume. Nutrients transported to the liver in the context are ultimately degraded in the liver cells to become energy sources or resynthesized, stored in the liver or released into the blood.
간장은 영양소의 흡수·대사·저장, 담즙생산, 요소형성, 삼투압 조절, 대사물 운반, 혈액 응고에 영향을 준다. 단당류(포도당 등)는 간장세포 내에서 글리코겐(glycogen)으로 합성(glycogenesis)되어 간장에 저장되며 필요에 따라 포도당으로 분해(glycolysis)되어 혈당 조절에 기여한다. 또 미토콘드리아(mitochondria)의 TCA cycle에서 에너지를 산출한다.Soy affects the absorption, metabolism and storage of nutrients, bile production, urea formation, osmotic pressure control, metabolite transport and blood coagulation. Monosaccharides (glucose, etc.) are synthesized as glycogen (glycogen) in hepatic cells, stored in the liver, and are degraded to glucose as needed to contribute to blood sugar control. It also calculates energy in the TCA cycle of mitochondria.
지방산은 간장세포의 미토콘드리아 내에서β산화를 받아 acetyl CoA가 된다. 이 acetyl CoA는 TCA cycle에서 산화되어 다량의 ATP를 방출하는 에너지원이 된다. 또 지방산은 콜레스테롤도 합성되며, 지방산이 글리세롤과 결합하는 것에 따라 중성 지방과 인지질이 합성된다. 간장에 저장되어 있는 지방(3∼5%)은 활발히 대사되며, 항지방간 인자(methionine, cholin, lecithin 등)의 작용으로 항상 일정량 이상의 지방은 증가하지 않는다.Fatty acids undergo β oxidation in the mitochondria of hepatic cells to become acetyl CoA. This acetyl CoA is oxidized in the TCA cycle and becomes an energy source that releases large amounts of ATP. Fatty acids are also synthesized in cholesterol and triglycerides and phospholipids are synthesized as fatty acids bind to glycerol. Fat stored in the liver (3-5%) is actively metabolized, and the action of anti-fatty liver factors (methionine, cholin, lecithin, etc.) does not always increase more than a certain amount of fat.
아미노산은 간장세포내의 단백질 즉, 알부민, 글로불린, 피브리노겐, 프로트롬빈, 리포프로틴 등으로 생합성되어 간장에 저장(단백질풀)되거나 혈중에 방출된다. 피브리노겐과 프로트롬빈은 혈액 응고에 필수적이며 또 리포프로틴은 지방의 혈중 운반에 꼭 필요한 것이다. 간장세포내에서의 아미노산은 탈아미노 작용(deamination) 혹은 아민기의 전이작용(trans-amination)에 의해 대사되며, 탈아미노 작용에서 생성된 케토산(keto acid)은 Krebs cycle에서 산화되어 에너지원이 되든지 케톤체(ketone body) 생성 또는 당생성에 이용된다. 탈아미노 작용에서 생성된 암모니아는 ornithin cycle에서 요소가 되어 소변으로 배설된다. 간장의 당신생(gluconeogenesis)은 아미노산, 예를 들면 알라닌 외에 젖산, 글리세롤 등 당이 아닌 물질에서 당이 만들어지는 것이다.Amino acids are biosynthesized into proteins in hepatic cells, such as albumin, globulin, fibrinogen, prothrombin, lipoprotein, and stored in the liver (protein pool) or released into the blood. Fibrinogen and prothrombin are essential for blood coagulation, and lipoprotein is essential for the transport of fat in the blood. Amino acids in hepatic cells are metabolized by deamination or trans-amination of amine groups. Keto acids produced during deamination are oxidized in the Krebs cycle to provide energy. It is used for the production of ketone bodies or for the production of sugar. The ammonia produced by the deaminoation acts as a urea in the ornithin cycle and is excreted in the urine. Gluconeogenesis in the liver is when sugar is made from non-sugar substances such as amino acids, such as alanine, lactic acid and glycerol.
간장세포에서는 각종 비타민 특히 A·D·B1·B2·엽산·B12등의 저장과 활성화가 행하여지고, 소장에서 지방 대사에 필요한 담즙산을 생성하며, 혈중의 이물(異物)·세균 등의 해독작용(detoxication)을 한다. 또한 이 피브린은 간장에서glucuronic acid와 결합하여 친수성이 되어 장내로 배설되며 장내 세균에 의해 환원되어 우로빌리루빈(urobilirubin)이 된다. 이것은 다시 우로비린(urobilins)로 산화되어 소변으로 배설하게 된다.Hepatic cells store and activate various vitamins, especially A, D, B 1 , B 2 , folic acid, and B 12 , and produce bile acids necessary for fat metabolism in the small intestine. Detoxication In addition, the fibrin is hydrophilic by binding to glucuronic acid in the liver, excreted into the intestine, and reduced by the intestinal bacteria to become urobilirubin. It is then oxidized to urobilins and excreted in the urine.
간장에 이상이 생기게 되면 당질대사, 지질대사, 단백질과 질소 대사, 아미노산 대사, 단백질 대사와 간성 뇌질환, 비타민 대사, 흡수 불량 등의 대사성 장애가 발생하고, 간염, 지방성간장, 간경변증 등으로 간장질환이 악화될 수 있다.If liver abnormalities occur, metabolic disorders such as carbohydrate metabolism, lipid metabolism, protein and nitrogen metabolism, amino acid metabolism, protein metabolism, hepatic brain disease, vitamin metabolism, and malabsorption occur, and hepatic disease is caused by hepatitis, fatty liver and cirrhosis. Can get worse.
간장 질환이란, 상기 물질대사 기능이상 및 생합성 기능이상에 기인하는 간 기능장해, 예를 들면 약물 등에 의한 급성 간염, 또는 이러한 급성 간염이 만성화한 만성 간염, 음주 등에 의한 지방간 또는 이들이 만성화한 만성 간염, 비루스 감염에 의한 비루스 감염, 또는 이것이 만성화한 만성 감염, 그리고 이상의 각 장해결과에 생기는 간경변 등의 다양한 간장 기능장해를 나타내는 질환을 말한다.Hepatic disease refers to liver dysfunction due to metabolic dysfunction and biosynthetic dysfunction, for example, acute hepatitis caused by drugs or the like, or chronic hepatitis caused by chronic acute hepatitis, drinking fatty liver, or chronic hepatitis caused by these chronic diseases, It refers to the disease which shows various liver dysfunctions, such as viral infection caused by viral infection, or chronic infection which has become chronic, and cirrhosis of each intestinal remedy.
마찬가지로, 간장 질환의 치료방법으로서는, 현재 간장기능 보존을 위한 요법, 예를 들면 안정요법, 식사요법 및 약물요법이 알려져 있다. 이들 요법 중 약물요법으로서는, 구체적으로 아미노산, 예를 들면 아스파라긴산, 티옥트산, 메티오닌, 티오프롤린, 글리신 및 글루타치온 등의 펩티드류, 간장 추출 엑기스, 간장 수해물, 태반 수해물, 글루크론산 유도체 및 감초에서 추출 정제한 글리틸리틴 등을 사용하는 요법이 있다. 그리고, 이들 약제 중, 글리틸리틴은 만성 간염에 기인하는 간장기능의 개선에 유효산 것으로 알려져 있지만, 이 글리틸리틴은 경구 투여에서는 무효하다는 투여상의 문제점을 갖고 있다.Similarly, as a method for treating hepatic disease, therapies for preserving hepatic function, for example, stable therapy, diet therapy and pharmacotherapy are known. Among these therapies, pharmacotherapy is specifically used in amino acids such as peptides such as aspartic acid, thioctic acid, methionine, thioproline, glycine and glutathione, soy extract extract, hepatic lysates, placental lysates, glucuronic acid derivatives and licorice. There is a therapy using extracted and purified glytilinine. Among these drugs, although glycitritin is known to be effective for improving hepatic function due to chronic hepatitis, the glycitritin has an administration problem that it is invalid for oral administration.
또한, 간장질환의 발생기전은 비루스 감염, 중독성 간염 외에는 해명되어 있지 않으며, 간장질환의 치료법도 안정요법 및 식사요법 등이 주로 이용되어 왔다. 그러나 근년, 예를 들면 간세포의 단백질 합성 및 RNA 합성을 부활시킴으로써 간섬유화 진전 억제작용을 갖는 말로틸레이트(malotilate)가 개발되었다. 그러나 이러한 말로틸레이트는 간경변의 치료에만 적용하는 것이 인정되고 있음에 불과하다.In addition, the pathogenesis of hepatic disease is not elucidated except by viral infection and addictive hepatitis, and the treatment of liver disease has been mainly used for stabilization therapy and diet therapy. In recent years, however, malotilate has been developed, which has the effect of inhibiting the progress of hepatic fibrosis by reactivating protein synthesis and RNA synthesis of hepatocytes. However, it is only recognized that such malolate is applied only to the treatment of cirrhosis.
또한, 그 작용 기전이 불명한 면역 부활제로서 시아니다놀이 개발되어, B형 비루스성 간염의 치료에 유효하다고 되어 있다. 그러나 이탈리아, 포르투갈에 있어서, 시아니다놀을 투여한 환자의 사망 사고가 발생했기 때문에, 일본에 있어서는 시아니다놀의 판매가 현재 금지되어 있다. 또한, 이러한 이유로 인하여 광범위한 간장질환의 치료 및 예방에 유효하고, 안정성이 우수한 약제 및 식품의 개발이 촉망되는 현실이다.In addition, Cyanidanool has been developed as an immune activator with unknown mechanism of action, and is said to be effective for the treatment of hepatitis B virus. However, in Italy and Portugal, the sale of cyanidanool is currently banned in Japan because a death accident occurred in a patient who administered cyanidinol. In addition, for these reasons, the development of drugs and foods effective in the treatment and prevention of a wide range of hepatic diseases, and excellent in stability is desired.
본 발명자는 간장을 보호할 수 있는 식품연구에 주력한 결과 천연 생약재인 인진쑥, 상황, 영지, 산사자, 호사자(원지), 달개비, 알로에, 복분자, 천궁, 계피, 구기자, 백출, 산수유, 곽향, 매실, 오갈피, 덩굴초, 백봉령, 어성초, 민들레를 혼합하여 섭취함으로써 간장보호 효과를 얻을 수 있음을 발견하고 본 발명을 완성하였다.As a result of focusing on research on foods that can protect the liver, the inventors found natural herbs such as Injin mugwort, Situary, Ganoderma lucidum, Sansa, Hosa (origin), Dalbi, Aloe, Bokbunja, Cheongung, Cinnamon, Gugija, Baekchul, Cornus, Kwakhyang, The present invention was completed by discovering that the hepatoprotective effect can be obtained by ingesting a mixture of plum, ogalpi, vine, baekbongnyeong, eoseongcho, and dandelion.
따라서, 본 발명의 목적은 간장보호 효과가 우수한 건강식품 조성물을 제공함에 있다.Accordingly, an object of the present invention is to provide a health food composition excellent in hepatoprotective effect.
본 발명의 상기 목적은 천연 약재들을 인진쑥 8 중량%, 상황 6 중량%, 영지 6 중량%, 산사자 4 중량%, 호사자 4 중량%, 달개비 4 중량%, 알로에 4 중량%, 복분자 4 중량%, 천궁 4 중량%, 계피 4 중량%, 구기자 4 중량%, 백출 4 중량%, 산수유 4 중량%, 곽향 4 중량%, 매실 4 중량%, 오갈피 4 중량%, 덩굴초 4 중량%, 백봉령 4 중량%, 하수오 4 중량%, 어성초 4 중량%, 민들레 4 중량%, 꿀 8%로 혼합하여 간장보호용 건강식품 조성물을 제조하고, 상기 조성물을 사용하여 동물실험을 실시하여 간장보호 효과를 확인함으로써 달성하였다.The object of the present invention is the natural medicinal herbs 8% by weight, situation 6% by weight, Ganoderma 6% by weight, hawthorn 4% by weight, 4% by weight of starfish, 4% by weight of arachnids, 4% by weight of aloe, 4% by weight of bokbunja, Cheongung 4%, Cinnamon 4%, Wolfberry 4%, Baekchul 4%, Cornus 4%, Wagyu 4%, Plum 4%, Ogalpi 4%, Vinegar 4%, Baekbongryeong 4% , 4% by weight of sewage, 4% by weight of eoseongcho, 4% by weight of dandelion, 8% of honey to prepare a health food composition for the protection of the liver, animal experiments were carried out using the composition to achieve the liver protection effect.
이하 본 발명의 구체적인 구성 및 효과를 실시예를 들어 설명하지만 식품종류의 선택 및 조성비의 변경 등은 건강식품의 효과를 저하시키고 당업자간에 권리의 범위를 의도적으로 무의미하게 변경을 꾀할 수 있음은 물론이며 이와 같은 수치 범위의 변경은 본 발명의 권리범위 내 속하는 것은 물론이다.Hereinafter, the specific configuration and effects of the present invention will be described with reference to examples, but the selection of food types and the change in composition ratio may deteriorate the effects of health foods and intentionally and intentionally change the scope of rights among those skilled in the art. Of course, such a change in numerical range is within the scope of the present invention.
본 발명의 바람직한 실시예에 따르면, 인진쑥 8 중량%, 상황 6 중량%, 영지 6 중량%, 산사자 4 중량%, 호사자 4 중량%, 달개비 4 중량%, 알로에 4 중량%, 복분자 4 중량%, 천궁 4 중량%, 계피 4 중량%, 구기자 4 중량%, 백출 4 중량%, 산수유 4 중량%, 곽향 4 중량%, 매실 4 중량%, 오갈피 4 중량%, 덩굴초 4 중량%, 백봉령 4 중량%, 하수오 4 중량%, 어성초 4 중량%, 민들레 4 중량%, 꿀 8%를 잘게 분쇄하여 분말로 가공한 다음 혼합하여 환 형태의 분말을 가공한다.According to a preferred embodiment of the present invention, 8% by weight of phosphorus mugwort, 6% by weight of velvet, 6% by weight of ganoderma lucidum, 4% by weight of lioness, 4% by weight of starfish, 4% by weight of arachnids, 4% by weight of aloe, 4% by weight of bokbunja, Cheongung 4%, Cinnamon 4%, Wolfberry 4%, Baekchul 4%, Cornus 4%, Wagyu 4%, Plum 4%, Ogalpi 4%, Vinegar 4%, Baekbongryeong 4% , 4% by weight of sewage, 4% by weight of eoseongcho, 4% by weight of dandelion, 8% of honey finely pulverized into a powder and then mixed to process the powder in the form of a ring.
생당쑥이라고 불리는 인진쑥(Artemisia Messerschmidtiana Besser)은 높이 1∼1.5m에 이르는 여러해살이풀이다. 인진쑥의 전초에는 정유(피넨, 테르피넨, 리모넨, 테르피네올, 찌네올), 방향족옥시카르본산(클로로겐산, 카페인산, 페롤라산), 플라보노이드, 옥시쿠마린(스코폴린, 스코폴레틴)이 있고, 요즘에는 움벨리페론도 분리확인되었다. 동의치료에서 염증약, 열내림약, 오줌내기약, 열물내기약으로 발열성황달, 간염, 담낭염 등에 쓴다.Artemisia Messerschmidtiana Besser, also called raw mugwort, is a perennial plant from 1 to 1.5m high. The outposts of Injin mugwort include essential oils (pinene, terpinene, limonene, terpineol, cineol), aromatic oxycarboxylic acids (chlorogenic acid, caffeic acid, perolanic acid), flavonoids and oxycoumarins (scopolline, scopoline). Nowadays, Umbelliferon has also been isolated. In motion therapy, it is used for inflammatory medicine, fever lowering medicine, urinary medicine, and fever tingling medicine, such as fever jaundice, hepatitis and cholecystitis.
산사자는 모과 열매처럼 쿠엘세틴, 오레아놀산을 함유하고 있기 때문에 이뇨작용을 하며, 비타민 B, C, 칼로틴, 클로로겐산 등을 함유하고 있어 산후복통, 숙취, 건위, 소화불량, 만성 설사에 효과적이고 위장의 활동을 조절하고 소화불량을 치료하는 효과도 있다.The hawthorn is diuretic because it contains quercetin and oleanoic acid like quince, and it contains vitamin B, C, carotene and chlorogenic acid, which is effective for postpartum abdominal pain, hangover, dryness, indigestion and chronic diarrhea. It also helps regulate gastrointestinal activity and treat indigestion.
호사자는 원지과의 다년초인 원지(遠志)라고도 불리우며, 뿌리는 굵고 길며 끝에서 몇 개의 원줄기가 무더기로 나와서 30 cm 내외로 자라며 거의 털이 없다. 꽃은 7∼8월에 피고 자주색이며 총상꽃차례에 드문드문 달린다. 꽃받침조각은 5개이고 뒤쪽과 밑의 것 2개는 선형(線形)이며 양쪽 2개는 꽃잎같이 생겼다. 꽃잎은 윗부분이 벌어지고 밑부분이 붙어 있으며 끝이 솔처럼 잘게 갈라진다. 삭과(果)는 편평하고 2개로 갈라진다. 한방에서는 뿌리를 원지라고 하며 거담 및 강장·강정제로 쓴다.Hosa is also called perilla, a perennial herb of the genusaceae. The roots are thick and long, and several stalks come out at the ends and grow to around 30 cm and have almost no hair. Flowers bloom in July-August, purple, sparsely hanging in inflorescences. Calyxes are 5, 2 at the rear and 2 at the bottom, linear and 2 like petals. Petals are open at the top, attached at the bottom, and chopped like a brush. The fruit is flat and split into two. In oriental medicine, the root is called Wonji, and it is used as expectorant, tonic and gangjeong.
달개비는 닭의장풀과에 딸린 한해살이 꽃으로 닭의장풀이라고도 한다. 키가 15∼50㎝이고 약으로 어린 잎과 줄기를 먹을 수 있다.It is a perennial flower attached to the chickweed grass family and is also called chickweed grass. It is 15-50cm tall and can eat young leaves and stems with medicine.
알로에(Aloe sp.)에는 알로인 C20H18O916∼20%, 알로에-에모딘, 나탈로인, 라바르베론, 수지 12%가 들어 있고 쓴맛강장약, 소화 및 식욕항진, 설사약으로 쓰이며 동의치료에서는 어린이감적, 변비때 하루 1∼2g을 쓴다.Aloe sp. Contains 16-20% of Aloe C 20 H 18 O 9 , Aloe-Emodine, Nataloine, Labarberon, 12% Resin, and is a bitter tonic, digestive and appetite, and diarrhea. In motion therapy, children's markers, constipation 1 ~ 2g is used a day.
복분자는 멍덕딸기(Rubus sachalinensis Lev.)의 선열매로 2.2%의 레몬산을 비롯한 유기산, 살리찐산, 카프론산, 개미산과 그의 염, 많은량의 펙틴, 카로틴(0.3㎎%), 비타민 B군, 포도당 4.3%, 과당 8%, 서당 6.5%, 탄닌질 0.3%, 찌아니딘클로리드 C27H31O6, 아세토인 C4H8O2, β-요논, 벤즈알데히드가 있다. 복분자 달임약은 동물실험에서 열내림작용과 강심이뇨작용을 하며, 동의치료에서는 복분자를 발한해열약으로 감기, 열성질병, 폐염, 기침, 강정강장약으로 쓴다.Bokbun is a fruit of Rubus sachalinensis Lev., Organic acid including 2.2% lemon acid, salinic acid, capronic acid, formic acid and salts thereof, large amount of pectin, carotene (0.3mg%), vitamin B group, glucose 4.3%, fructose 8%, sucrose 6.5%, tannins 0.3%, thianidine chloride C 27 H 31 O 6 , acetoin C 4 H 8 O 2 , β-yonone, benzaldehyde. Bokbunja decoction is a fever lowering effect and cardiac diuresis in animal experiments. In motion therapy, Bokbunja antipyretic fever is used as cold, febrile disease, pneumonia, cough, and gangjeong tonic.
천궁은 산천궁(Ligusticum jeholense Kitag.)의 뿌리로 정유, 쿠마린 등을 성분으로 함유하고 진정작용을 한다.Cheongung is the root of Sangusti (Ligusticum jeholense Kitag.) And contains essential oils, coumarins, and soothing functions.
계피[Zanthoxylum piperitum (L.) DC.]는 산초나무의 열매껍질 및 열매로 열매껍질에는 정유가 2∼4% 있는데, 주성분은 디펜텐 C10H16(54%), 찌트로넬랄 C10H18(8%), l-β-펠란드렌 C10H16(54%), 게라니올, 찌트로넬롤 등으로 이뤄져있다. 또한 열매에는 매운맛 성분으로 산솔 Ⅰ과 Ⅱ가 5∼8% 들어있는데 이는 국소마비작용이 있으며 열매가 여물수록 작용이 강해지고, 여러 가지 병원성세균에 대한 억균작용을 한다. 동의치료에서는 방향성건위약 염증약으로 위장염, 위확장증, 위하수 때에 쓰며 기타 오줌내기약, 국소흥분약, 벌레떼기약으로 사용한다.Cinnamon [Zanthoxylum piperitum (L.) DC. ] The fruit peel to the fruit peel and fruit of the Japanese pepper tree, the refinery there is 2-4%, the main component is dipentene C 10 H 16 (54%) , blackbird Trojan nelral C 10 H 18 (8%), l-β-phellandrene C 10 H 16 (54%), geraniol and chitronellol. In addition, the fruit contains 5-8% of Sansol Ⅰ and Ⅱ as a spicy ingredient, which has local paralysis effect and the stronger the fruit, the more bactericidal activity against various pathogenic bacteria. In motion therapy, it is an aromatic dry placebo inflammatory drug used for gastroenteritis, gastric dilatation and stomach and sewage. It is also used as a urinary medicine, topical excitement medicine, insect repellent medicine.
상황(Phellinus linteus)은 소나무비늘버섯과(Hymenochaetaceae)의 진흙버섯속(Phellinus)에 속하는 백색부후균으로, 자실체 추출물에서 96.7%의 매우 강력한 종양저지율을 나타내며, 최근에 균사체 추출물의 항종양작용, 면역조절이 알려지고 있다. Phellinus linteus is a white fungus belonging to the genus Phellinus of the family Hymenochaetaceae, and has a very strong tumor inhibition rate of 96.7% in fruiting body extracts. Regulation is known.
구기자(Lycium chinense Miller)는 구기자나무 열매로 비타민 0.1%, 카로티노이드인 제아크산틴이 있고, 최근 생물학적활성물질인 스코플레틴을 분리확인하였다. 또한 카로티노이드와 스테린도 분리하였는데 이것은 피살리엔과 β-시토스테린이다. 구기자에는 혈압을 내리우는 작용이 있으며 혈액의 콜레스테린량을 줄여 동맥경화의 예방과 치료에 쓰인다. 동의치료에서는 열매를 보약으로 허리아픔, 무력증, 어지럼증, 머리아픔, 소갈에 쓰며 오래 먹으면 뼈를 든든하게 하고 몸을 가볍게 하며 흰머리를 검게 하고 눈을 밝게 하며 추위와 더위도 타지 않고 오래 산다는 말이 전해오고 있다.Gojija (Lycium chinense Miller) is a fruit of Goji berries, vitamins of 0.1%, carotenoids zeaxanthin, and recently identified the biologically active scoplatin. In addition, carotenoids and sterins were also isolated, which are pisalien and β-cytosterin. Gojija has the effect of lowering blood pressure and reducing the amount of cholesterol in the blood is used to prevent and treat atherosclerosis. In motion therapy, the fruit is used as a supplement to lower back pain, helplessness, dizziness, head pain, and oxal, and it is said that if you eat it for a long time, it will strengthen your bones, lighten your body, darken your gray hair, brighten your eyes, and live long without cold and heat. .
백출은 높이 약 80m에 이르는 여러해살이풀인 삽주[Atractylodes japonica (Koidz.) Kitag]의 뿌리 또는 뿌리줄기로 창출이라고도 불리운다. 봄 또는 가을에 캐서 물에 씻어 잔뿌리를 다듬고 햇볕에 말린 것을 창출이라 하고, 굵고 덩어리진 것을 골라 겉껍질을 벗긴 것을 백출이라 한다. 뿌리줄기에는 약 1.5%의 정유와 카로틴, 이눌린, 고무질, 알칼로이드반응이 있다. 정유는 진정작용, 중추신경마비작용, 혈압내림작용, 오줌내기작용이 있고 방향성건위약으로 소화불량증에 널리 쓰이며, 동의치료에서는 몸안에 있는 여분의 물을 몸밖으로 내보내는 작용이 있다는데로부터 콩팥기능장애로 소화관이나 피하조직 중에서 수분대사의 부전에 오줌내기, 땀내기약으로 동의처방에 배합하는 매우 중요한 동약이다. 또한, 설사와 토하는 것을 멈추는데, 당뇨병, 폐결핵과 기침, 류마치스, 통풍, 열성질병, 감기, 간장질병, 비장질병, 악성종양 등에 쓰인다.It is also known as the root or root stem of Atractylodes japonica (Koidz.) Kitag, a perennial herb, about 80 m high. Casseroles in spring or autumn are washed with water to make fine roots and dried in the sun. Root stem contains about 1.5% of essential oils, carotene, inulin, gum and alkaloids. Essential oils have sedation, central nerve palsy, blood pressure lowering, and urinary action, and they are widely used for dyspepsia as a directional placebo. In motion therapy, extra water in the body is released out of the body. It is a very important medicine that is formulated in the synergistic prescription as urinary and sweating medicines in the digestive tract or subcutaneous tissues. It also stops diarrhea and vomiting. It is used for diabetes, pulmonary tuberculosis and cough, rheumatism, gout, febrile disease, cold, liver disease, spleen disease, and malignant tumors.
산수유(Macrocarpium officinale Sieb. et Zucc.)는 산수유나무 열매껍질로 열매에는 결정성유기산, 몰식자산, 사과산, 포도주산 등이 있으며 열매껍질에는 이리도이드배당체인 모르로니시드, 로가닌 등이 있다. 동의치료에서는 자양강장약, 수렴약으로 콩팥을 보하며 땀을 자주 흘리고 오줌이 조금씩 자주 나올 때, 허리아픔, 달거리가 고르지 않을 때 사용한다.Cornus (Macrocarpium officinale Sieb. Et Zucc.) Is a fruit bark of the hawthorn tree, which includes crystalline organic acids, glutinous assets, malic acid, and grape acids, and the fruit shells include iridonide glycosides such as moronisides and loganins. In motion therapy, nourishment tonic and astringents are used to see the kidneys, and when sweating frequently and urine comes out little by little, it is used when the back pain and the moon are uneven.
방아풀[Agastache rugosa(Fisher et Meyer) O. Kuntze]이라 불리우는 곽향은 높이 1∼1.5m에 이르는 여러해살이풀로 정유는 전초에 약 0.3%, 잎에 0.2∼2.3%, 꽃이삭에 5%, 줄기에 0.1% 있다. 정유의 주성분은 메틸카비골, 아니스알데히드, 아네톨, d-리모넨, 세스쿠이테르펜, α-피넨, β-피넨, α-리모넨, 옥사논, P-찌몰, 리날롤이 있고, 플라보노이드로서 아카쩨틴, 틸리아닌, 리나린, 아가스타코시드가 분리되었다. 동의치료에서 건위약, 구풍약, 소화약, 열내림약으로 더위를 먹거나 먹은 것이 체한 때, 감기, 머리아픔과 구토설사때 쓴다. 또한 피질병, 종양치료약으로도 드물게 사용하며 특히, 비장과 위장병에 쓰이는 중요한 약이다.Called Agastache rugosa (Fisher et Meyer) O. Kuntze, the perennial herb is 1-1.5m high, essential oil is about 0.3% for outpost, 0.2-2.3% for leaves, 5% for flowers, 0.1% on the stem. The main components of essential oils are methylcarbigol, anisealdehyde, anetol, d-limonene, sesquiterpene, α-pinene, β-pinene, α-limonene, oxanone, P-chimol, linalol, and acachettin as flavonoid , Tilianin, linarin, and agathacoside were isolated. In motion therapy, it is used for cold, head pain and vomiting diarrhea when eating or eating heat with dry stomach medicine, old wind medicine, digestive medicine, heat lowering medicine. It is also rarely used as a drug for the treatment of cortex and tumors, and is an important medicine especially for the spleen and gastrointestinal diseases.
매실은 간장과 담을 다스리며 세포를 튼튼히 하고 혈액을 정상으로 만들며 번열을 내리고 사지통증을 멈추게 한다. 또한 내장의 열을 다스리고 갈증을 조절하며 냉을 없애고 설사를 멈추게 한다. 그리고 월경불순, 염증대하, 대변불통, 대변하혈, 피오줌, 중풍, 경기에 사용한다.Plums rule the liver and the phlegm, strengthen the cells, make the blood normal, reduce heat and stop limb pain. It also controls the heat of the intestines, controls thirst, eliminates cold and stops diarrhea. And menstrual irregularity, inflammation, stool irritation, stool bleeding, pissing, palsy, is used in the game.
오갈피는 오갈피나무(Acanthopanax sessiliflorum Seeman)의 나무껍질로 배당체인 아칸토시드, 탄닐질, 정유, 비타민 A와 C, 기름이 있다. 오갈피에는 물에 풀리는 다당류가 있는데 이는 약초에 들어있는 성분들을 물에 잘 풀리게 하며 흡수를 돕는다. 동의치료에서는 강장, 이수, 거습, 아픔멎이약으로 몸이 쇠할 때와 관절염, 신경아픔, 신경성소화불량증, 각기, 감기, 허리아픔, 임신때의 아픔, 위를 든든하게 하는데 쓰인다.Ogalpi is a bark of the Acanthopanax sessiliflorum Seeman, which contains glycosides, acanthosides, tanyls, essential oils, vitamins A and C, and oil. Ogalpi has polysaccharides that are soluble in water, which helps to loosen and absorb the ingredients in herbs. In motion therapy, it is used to strengthen the body, torture, roughness, pain and weakness, arthritis, neuropathy, anorexia, individual pain, cold, back pain, pregnancy pain, and stomach.
덩굴초는 닭의장풀과의 1년생 덩굴식물로 산기슭의 습기 있는 곳에서 자란다. 줄기는 뭉쳐나고 가지를 치며 연하고 길이는 80 cm 정도이며, 잎은 어긋나고 긴 잎자루가 있고, 심장형인데 끝은 매우 뾰족하고 가장자리는 밋밋하다. 7∼8월에 백색 꽃이 가지 끝과 줄기 끝에 2∼3개씩 피는데 지름이 5∼6 mm이다. 꽃받침은 1∼3맥이 있고 길이 4 mm 정도이며 수술대에 꼬불꼬불한 털이 있고, 열매는 삭과(果)로 3개의 능선(稜線)이 있고 타원형이며 길이 8∼11 mm로 털이 없다. 종자는 2∼6개씩 들어 있으며 겉에는 잔 돌기가 있다. 어린 줄기와 잎은 식용한다.The vine is a yearly vine plant of the chickweed family and grows in damp areas at the foot of the mountain. Stems are clustered, branched, light, about 80 cm long, leaves alternate, long petioles, heart-shaped, with sharp tips and flat edges. In July-August, 2 ~ 3 white flowers bloom at the end of branches and stems, 5 ~ 6 mm in diameter. Calyxes have 1 to 3 veins, about 4 mm long, with curly hairs on the operating table, and fruit has three ridges with oak, oval, 8-11 mm long, without hairs. Seeds are contained in 2-6 pieces, and the outer surface has small bumps. Young stems and leaves are edible.
백봉령[Poria cocos (Schw.) Wolf.]의 성분은 다당류인 파키만이 약 94%, 트리테르펜산, 당, 무기물, 에르고스테롤이 있으며, 동의치료에서 오줌내기약, 진정약으로 오줌이 잘 나오지 않을 때, 붓기와 물고임, 먹은 것이 내려가지 않고 입맛이 없을 때, 위내정수, 가슴활랑거림, 잠을 이루지 못할 때에 쓴다. 또한 근육의 간장대성경련과 어지럼증에도 쓴다.The content of Poria cocos (Schw.) Wolf. Consists of about 94% of the polysaccharide pakiman, triterpenic acid, sugars, minerals, and ergosterol. When not, swelling, bite, eat when things go down and have no appetite, gastric constant, heart swelling, sleep can not be used. It is also used for muscle hepatic cramps and dizziness.
하수오는 붉은조롱(polygonum multiflorum Thunb.)의 뿌리로 옥시메틸안트라키논유도체 1.8%, 농마 약 45%, 기름 약 3%, 레찌틴 3.7%, 물에 풀리는 물질 약 26%가 들어 있다. 동의치료에서는 하수오를 산후 및 노인성변비, 옴과 습진 등 피부병에 쓴다. 강장, 보혈 작용은 지황뿌리나 천문동보다 세다고 한다.Sewage is the root of a red gourd (polygonum multiflorum Thunb.) Containing 1.8% oxymethylanthraquinone derivatives, about 45% horses, about 3% oil, 3.7% lecithin, and about 26% loosening material. In motion therapy, sewage is used for skin diseases such as postpartum and senile constipation, scabies and eczema. Tonic, blood is said to be stronger than Chihwang Root or Astronomical Dong.
어성초(Hottuynia cordata Thunb.)는 약모밀이라고도 하며 높이 15∼30㎝ 되는 여러해살이풀이다. 전초는 염증약, 이뇨해독약으로 임질과 요도염, 방광염, 자궁염, 폐염, 기관지염, 물고임, 무좀치루, 탈홍, 악창 등에 사용하며 차처럼 달여서 매일 마시면 동맥경화를 예방할 수 있다.Hottuynia cordata Thunb. Is a perennial herb, also known as weak wheat, 15-30 cm high. Outpost is an inflammatory drug and diuretic poisoning agent, which is used for gonorrhea, urethritis, cystitis, uterus, pneumonia, bronchitis, bite, athlete's foot, browning, and swelling.
영지는 담자균류 민주름목 구멍장이버섯과의 버섯으로 불로초라고도 한다. 여름에 활엽수 뿌리에서 발생하여 땅 위에도 돋는다. 한방에서는 강장·진해·소종(消腫) 등의 효능이 있어 신경쇠약·심장병·고혈압·각종 암종에 사용한다. 영지는 갓자루가 단단한 각피로 싸여 있고 니스를 칠한 것 같은 광택이 있어 일본에서는 만년버섯, 중국에서는 영지라고 하여 한약재료로 귀하게 사용하고 장식용으로도 이용된다.Ganoderma lucidum is a fungus that is also called Bulchocho. It occurs in the roots of hardwoods in summer and also sprouts on the ground. In oriental medicine, it is effective in tonic, Jinhae, and small sarcoma. Ganoderma lucidum is covered with a hard skin and has a glossy appearance like varnish. It is used as an herbal medicine in Japan as a mushroom in Japan and as a territory in China.
민들레(Taraxacum Platycarpum H.dahlsi.)는 간장담도질병치료약, 건위소화약, 밥맛을 돋구는 약으로 특히 회복기환자들의 영양식사에 널리 쓰이다. 동의치료에서 건위약, 오줌내기약, 쟁혈약으로 소화불량, 위염, 위아픔, 젖앓이, 변이 굳고 오줌을 누지 못하는데, 감기, 인후염, 눈병 등 곪는데 쓰인다.Dandelion (Taraxacum Platycarpum H.dahlsi.) Is a medicine for treating hepatobiliary diseases, peptic digestion, and rice flavoring. In motion therapy, it is a placebo, urinary medicine, puff medicine, indigestion, gastritis, stomach pain, lactation, stiffness and squeezing of the urine, which is used to stop colds, sore throat, and eye disease.
본 발명은 식품으로 인체에 전혀 해롭지 않고 우리가 항상 먹고 있는 식품원료 중에서 들에서 자생하고 있는 가식성(edible) 식품원료인 인진쑥 , 상황, 영지, 산사자, 호사자(원지), 달개비, 알로에, 복분자 , 천궁, 계피, 구기자, 백출, 산수유, 곽향, 매실, 오갈피, 덩굴초, 백봉령, 하수오, 어성초, 민들레를 미세하게 분쇄한 후, 건조하여 혼합분말가루로 만든 것으로, 인체에 해로운 것이 없고 그 성분 중에는 간장보호 등의 신진대사 작용에 관여하는 것이 있으므로 유용한 것이다.The present invention is not harmful to the human body as a food at all, we are always edible food raw materials that grow in the field of edible edible (edible) raw materials, the situation, ganoderma lucidum, hawthorn, lions (origin), coriander, aloe, bokbunja Finely pulverized, Cheongung, Cinnamon, Wolfberry, Baekchul, Cornus, Kwakhyang, Plum, Ogalpi, Vinegar, Baekbongryeong, Shouo, Echochocho, and Dandelion, and then dried and mixed with powder. It is useful because some of them are involved in metabolic action such as liver protection.
본 발명의 건강식품 조성물에 함유되는 성분은 모두 생약재, 식품재료 및 식품으로 사용되는 것으로, 복용 또는 섭취시 인체에 대한 안전성이 우수하다.Ingredients contained in the health food composition of the present invention are all used as herbal medicines, food ingredients and foods, it is excellent in safety to the human body when taking or ingesting.
한편, 본 발명의 구성에 따른 작용을 설명한다.질환이 있을 경우에는 얼굴이 황색을 띄우고 소변의 배출이 안되고 부종이 생기며 습기와 열기를 싫어하는 기관인 간장을 보호하기 위하여, 인진쑥을 주된 약으로 첨가하는데 습기를 제거하고 황달을 제거하여 간장을 돕는 역할을 하며, 상황과 영지는 기혈(氣血)을 보(補)하여 강장시키는 역할을 하며, 어성초와 민들레는 청열(淸熱)하고 간의 독성물질을 풀어주는 작용을 하고, 산사자, 백출, 곽향, 백복령은 약의 소화를 도와주는 역할을 하며, 복분자, 매실, 산수유는 강장시키면서 약효가 흡수되지 않고 체외로 배설되는 것을 방지하는 역할을 하며, 알로에는 청열의 효과를 나타내며, 천궁, 계피, 호사자는 기의 순환을 도와주는 역할을 하며, 구기자와 하수오는 혈액의 생성을 도와주는 역할을 하며, 오가피는 습기를 제거하면서 근골을 강화시키는 역할을 하며, 달개비와 덩굴초는 어성초와 민들레의 작용을 보조해 주는 역할을 하며, 꿀은 환제조시 베이스로 사용된다.본 발명에 따른 바람직한 식품 조성물의 제형은 통상의 방법에 따라 분말화한 것이지만, 열수 또는 유기용매로 추출하여 담체를 넣어 건조한 후 캡슐화 하거나 기타 정제, 과립, 분말, 음료, 죽 등의 형태로 제형화할 수 있다.On the other hand, the operation according to the configuration of the present invention will be described. If there is a disease, the face is yellowish, urine is not discharged, edema occurs, and in order to protect the liver, an organ that does not like moisture and heat, phosphorus mugwort is added as a main medicine. It removes moisture and removes jaundice to help the liver. The situation and ganoderma play a role to strengthen and bolster blood vessels. It acts to release, Sansa, Baekchul, Gwakhyang, Baekbokyeong serves to help the digestion of the drug, Bokbunja, plum, and cornus milk to prevent the drug is not absorbed and excreted outside the body while tonic, Aloe It has the effect of clearing, celestial, cinnamon, and porridge help to circulate Qi, and goji and sewage help to produce blood. The blood acts to strengthen the musculature while removing moisture, and the cochlea and vines assist the action of fish and dandelion, and the honey is used as a base in the manufacture of pills. Is powdered according to a conventional method, but may be extracted with hot water or an organic solvent, put in a carrier, dried and encapsulated, or may be formulated in the form of other tablets, granules, powders, beverages, porridge and the like.
본 발명 간장보호용 건강식품 조성물의 바람직한 실시예를 들면 다음과 같다. 한편 하기 실시예 1에서 첨가되는 꿀은 당업계에서 환형태의 한약재를 제조하기 위하여 첨가되는 성분으로 알려져 있다.Examples of the health food composition for protecting the liver of the present invention are as follows. Meanwhile, honey added in Example 1 is known in the art as an ingredient added to prepare a medicinal herb in a cyclic form.
실시예 1 : 환(丸)형태의 간장보호용 조성물(단위 : 전체 100에 대한 중량%)Example 1 Composition for Hepatoprotection in Ring Form (Unit: 100% by weight)
인진쑥 8 중량%Injin mugwort 8% by weight
상황 6 중량%Situation 6% by weight
영지 6 중량%Ganoderma lucidum 6 wt%
산사자 4 중량%Sun Lion 4% by weight
호사자(원지) 4 중량%Dead lion (raw) 4% by weight
달개비 4 중량%4% by weight
알로에 4 중량%Aloe 4 wt%
복분자 4 중량%Bokbunja 4% by weight
천궁 4 중량%Cheongung 4% by weight
계피 4 중량%Cinnamon 4 wt%
구기자 4 중량%Wolfberry 4 wt%
백출 4 중량%4 wt%
산수유 4 중량%Cornus 4% by weight
곽향 4 중량%Outline 4% by weight
매실 4 중량%4% by weight of plum
오갈피 4 중량%Ogalpi 4 wt%
덩굴초 4 중량%4% by weight of vines
백봉령 4 중량%Baekbong-ryeong 4 wt%
하수오 4 중량%Sewage 4 wt%
어성초 4 중량%Eoseongcho 4% by weight
민들레 4 중량%꿀 8%Dandelion 4% by weight honey 8%
이하, 본 발명의 실시예에 따른 간장보호 효과를 측정하기 위한 동물실험과 그 결과를 제시한다.Hereinafter, an animal experiment for measuring the hepatoprotective effect according to an embodiment of the present invention and the results are presented.
실험예 1 : 본 발명 간장보호용 건강식품 조성물이 사염화탄소에 의한 급성 간장장해에 미치는 영향Experimental Example 1 Effect of the Hepatoprotective Health Food Composition of the Invention on Acute Hepatic Injury by Carbon Tetrachloride
실험동물로는 체중 200g 내외의 스프라그-돌리(Sprague-Dawley)계 흰쥐(rat)를 항온, 항습이 유지되는 동물사육실에서 1주일 이상 적응시킨 후, 일반상태를 관찰하여 외관상 건강한 동물을 선별하여 실험에 사용하였다.As experimental animals, Sprague-Dawley rats with a body weight of about 200 g were allowed to adapt to the animal breeding room where constant temperature and humidity were maintained for at least one week. It was used for the experiment.
상기와 같이 선별된 흰쥐 50마리를 각각 10마리씩 5개군으로 나누어 본 발명 간장보호용 건강식품 조성물의 용량을 달리하여 투여하였다. 사염화탄소(CCl4)와 옥수수기름(corn oil)을 1:4(v/v%)로 혼합하여 체중 100g 당 0.2 mL씩 경구투여하고, 정상대조군(A)과 사염화탄소 투여 대조군(B)에는 식염수를 투여하고, 실험군에는 본 발명 건강식품 조성물을 0.9% 식염수에 현탁하여 각각 1㎎/㎏/day(C), 20㎎/㎏/day(D), 100㎎/㎏/day(E)로 정맥주사로 투여하였으며, 그 투여기간은 4일간으로 투여일정은 하기 표 1과 같다.The 50 rats selected as above were divided into 5 groups of 10 rats each, and were administered at different doses of the hepatoprotective health food composition of the present invention. Carbon tetrachloride (CCl4) and corn oil are mixed at 1: 4 (v / v%) and orally administered by 0.2 mL per 100 g of body weight, and saline is administered to the normal control group (A) and carbon tetrachloride control group (B). In the experimental group, the health food composition of the present invention was suspended in 0.9% saline solution and injected intravenously at 1 mg / kg / day (C), 20 mg / kg / day (D) and 100 mg / kg / day (E), respectively. It was administered, the administration period is four days as shown in Table 1 below.
상기와 같이 약물을 투여한 후 제 5일에는 미리 12시간 단식 후 마취상태에서 심장의 혈액을 채취하여 혈청 효소의 활성을 측정한 결과 표 2와 같이 나타났다.On day 5 after the drug was administered as described above, blood was collected from the heart under anesthesia after 12 hours of fasting, and the activity of serum enzymes was measured as shown in Table 2 below.
실험결과 본 발명 간장보호용 건강식품 조성물의 투여량을 증가시킬수록 간장보호 효과가 현저하게 향상되는 것을 알 수 있었다.Experimental results showed that the hepatoprotective effect is remarkably improved as the dose of the present invention is increased.
실험예 2 : 본 발명 간장보호용 건강식품 조성물과 알파토코페롤의 간장보호 효과 비교Experimental Example 2: Comparison of the hepatoprotective effect of the present liver food health care composition and alpha tocopherol
간장보호 효과를 갖는 것으로 알려진 알파토코페롤과 본 발명 간장보호용 건강식품 조성물과의 간장보호 효과를 비교하기 위하여 상기 실험예 1과 같이 흰쥐를 이용하여 본 발명 간장보호용 건강식품 조성물은 20 ㎎/㎏/day, 토코페롤은 350 ㎎/㎏/day의 용량을 투여하였고, 각 실험군의 생쥐 혈액을 채취하여 S-AST와 A-ALT를 비교하였다.In order to compare the hepatoprotective effect of the alpha-tocopherol known to have a hepatoprotective effect and the hepatoprotective health food composition of the present invention using the rat as in Experiment 1, the hepatoprotective health food composition of the present invention is 20 mg / kg / day Tocopherol was administered at a dose of 350 mg / kg / day, and blood of each experimental group was collected to compare S-AST and A-ALT.
실험결과 표 3에 나타낸 바와 같이 본 발명 간장보호용 건강식품 조성물 투여시 토코페롤보다 오히려 더 우수한 간장보호 효과를 나타냄을 확인할 수 있었다.Experimental results As shown in Table 3 it can be seen that the administration of the present invention, hepatoprotective health food composition showed a better hepatoprotective effect than tocopherol.
이상의 실시예와 실험예에서 설명한 바와 같이 본 발명에 따르면 상기의 간장보호용 건강식품을 제공하고, 사용한 경우 부작용 없이 사용자에게 만족감을 주는 뛰어난 효과가 있으며 간장 보호에 뛰어난 효과가 있으므로 건강식품산업상 매우 유용한 발명인 것이다.According to the present invention as described in the above Examples and Experimental Examples, the above-described hepatoprotective health foods are used, and when used, there is an excellent effect of satisfying the user without side effects, and is very useful in the health food industry because it has an excellent effect on the protection of the liver. It is an invention.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0045720A KR100376305B1 (en) | 2000-08-07 | 2000-08-07 | Healthy food composition for protecting hepatic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0045720A KR100376305B1 (en) | 2000-08-07 | 2000-08-07 | Healthy food composition for protecting hepatic |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020012434A KR20020012434A (en) | 2002-02-16 |
KR100376305B1 true KR100376305B1 (en) | 2003-03-17 |
Family
ID=19682121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0045720A KR100376305B1 (en) | 2000-08-07 | 2000-08-07 | Healthy food composition for protecting hepatic |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100376305B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020057854A (en) * | 2002-04-17 | 2002-07-12 | 김대도 | Ry eneagedrink |
KR100604354B1 (en) | 2004-06-04 | 2006-07-25 | 최서형 | Pharmaceutical composition comprising the crude drug extract for preventing and treating liver disease |
KR102043813B1 (en) * | 2018-12-26 | 2019-11-12 | 이창원 | Composition for liver protection against alcoholic liver damage |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040031121A (en) * | 2002-10-04 | 2004-04-13 | 이상호 | Manufacturing methode for health of support food |
KR20040032288A (en) * | 2002-10-09 | 2004-04-17 | 서경석 | Health food comprising natural Ganoderma Lucidum Karst components and method for the same |
KR20050079256A (en) * | 2004-02-05 | 2005-08-10 | 주식회사 리젠 바이오텍 | Composition for preventing and treating allergic diseases comprising extracts of houttuynia cordata and rubus coreanus |
KR100649128B1 (en) * | 2005-08-10 | 2006-11-27 | 이수복 | Manufacturing method of functional food composition including maesil |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000037814A (en) * | 1998-12-02 | 2000-07-05 | 최수부 | Healthy food contained natural medicine materials |
-
2000
- 2000-08-07 KR KR10-2000-0045720A patent/KR100376305B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000037814A (en) * | 1998-12-02 | 2000-07-05 | 최수부 | Healthy food contained natural medicine materials |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020057854A (en) * | 2002-04-17 | 2002-07-12 | 김대도 | Ry eneagedrink |
KR100604354B1 (en) | 2004-06-04 | 2006-07-25 | 최서형 | Pharmaceutical composition comprising the crude drug extract for preventing and treating liver disease |
KR102043813B1 (en) * | 2018-12-26 | 2019-11-12 | 이창원 | Composition for liver protection against alcoholic liver damage |
Also Published As
Publication number | Publication date |
---|---|
KR20020012434A (en) | 2002-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101445010B1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition, preparative method and usage thereof | |
Upton | Stinging nettles leaf (Urtica dioica L.): Extraordinary vegetable medicine | |
Kumar et al. | Recent trends in potential traditional Indian herbs Emblica officinalis and its medicinal importance | |
Panda | Handbook on medicinal herbs with uses: medicinal plant farming, most profitable medicinal plants in India, medicinal plants farming in India, plants used in herbalism, medicinal herbs you can grow, medicinal herbs and their uses, medicinal herbs, herbal & medicinal plants, growing medicinal herb, most profitable medicinal herbs growing with small investment, herbal medicine herbs | |
Kulkarni et al. | Indian gooseberry (Emblica officinalis): Complete pharmacognosy review | |
KR100574097B1 (en) | Functional food compositions having the effect on eliminating an alcoholic hangover and improvement of liver function | |
KR100976816B1 (en) | Composition for solving hangover and improving bowel and kidney function, and process for preparing the same | |
KR100373501B1 (en) | An antistress composition for a stress prevention and treatment | |
Hutchens | A Handbook of Native American Herbs: The Pocket Guide to 125 Medicinal Plants and Their Uses | |
CN104247913A (en) | Health rice vermicelli | |
KR100376305B1 (en) | Healthy food composition for protecting hepatic | |
JP3502072B2 (en) | Health food composition for protecting liver (Healthy food composition for protecting hepatic) | |
KR101058421B1 (en) | Herbal dietary supplement and its manufacturing method | |
KR100506622B1 (en) | Healthy food composition and method for producing the same | |
KR100509983B1 (en) | Healthy food composition for accelerating growth | |
KR20100077781A (en) | Method for preparing functional powder to improve erectile dysfunction and assistance food comprising the functional powder | |
CN107156829A (en) | A kind of full nutrition formula food suitable for hepatopath | |
CN109527577A (en) | A kind of composition with sobering up and liver protecting functions | |
KR20160147424A (en) | An enzyme composition for treating metabolic disorders including extracts wasong | |
KR102322276B1 (en) | Beverage composition for preventing obesity and relieving edema | |
Gillani et al. | Development and Characterisation of Fig (Ficus carica) Leaves Tea with Special Reference to Hypoglycemic Effect: Ficus Leaves Tea for Hypoglycemia | |
KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
KR101992174B1 (en) | Tablet-type composition for preventing and relieving hangover, and protecting hepatic caused by alcohol containing medical herbs | |
CN112546087A (en) | A pharmaceutical composition for caring skin and oral cavity, and its preparation method | |
CN111658720A (en) | Traditional Chinese medicine composition for health preservation, health preserving pill and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090305 Year of fee payment: 7 |
|
LAPS | Lapse due to unpaid annual fee | ||
G170 | Publication of correction |